

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Cancer</b>				
Leukemia	Not applicable	<p><i>In vitro</i> studies suggest that targeting chemotherapeutics to the mitochondria could help treat chemoresistant leukemias. In primary leukemia cells and chlorambucil-resistant leukemia cell lines, chlorambucil conjugated to a mitochondria-targeting peptide showed greater potency than chlorambucil alone. Ongoing work includes testing the conjugate in animal models of cancer.</p> <p>The nitrogen mustard-type, DNA-alkylating agent Leukeran chlorambucil is marketed by GlaxoSmithKline plc to treat chronic lymphocytic leukemia (CLL).</p> <p><b>SciBX 4(18); doi:10.1038/scibx.2011.509</b>  <b>Published online May 5, 2011</b></p>	<p>Patent applications filed; available for licensing through the MaRS Innovation Centre  <b>Contact:</b> Judith Blumstock, MaRS Innovation Centre, Toronto, Ontario, Canada            e-mail: <a href="mailto:information@marsinnovation.com">information@marsinnovation.com</a></p>	<p>Fonseca, S.B. <i>et al. Chem. Biol.</i>; published online April 22, 2011;            doi:10.1016/j.chembiol.2011.02.010  <b>Contact:</b> Shana O. Kelley, University of Toronto, Toronto, Ontario, Canada            e-mail: <a href="mailto:shana.kelley@utoronto.ca">shana.kelley@utoronto.ca</a></p>